When docetaxel emerged as the only treatment to improve survival among men with metastatic castrate-resistant prostate cancer (mCRPC) [1] , little did the oncology community realise that it might prove to be the first stage of a potential new era in the provision of care for the disease. Just 6 years after the landmark docetaxel trial, evidence was reported showing that two novel treatments--the chemotherapy drug cabazitaxel [2] and the hormonal agent abiraterone [3] --could further extend the survival of men with mCRPC who had already received docetaxel. Furthermore, the literature suggests that various other agents for this indication are on the horizon.
This supplement provides a timely update on the current and forthcoming therapeutic arena for men with mCRPC. Heather Payne and co-authors set the scene with a thorough overview of the evolution of the current paradigm for mCRPC management. Amit Bahl and Raj Persad then take up the narrative, exploring the latest therapeutic developments in mCRPC, and considering what the near future might bring. Zafir Malik looks at some of the practical questions that will need to be tackled in the clinical arena; notably, given a choice of options for mCRPC management post-docetaxel, how can they best be combined or sequenced to maximise the benefits for the individual patient? Of the emerging treatments, cabazitaxel is, at the time of writing, the only one to be licensed in Europe, and is hence already available at the clinical frontline, outside of the research setting. It is particularly useful, therefore, to have Anna Lydon's overview of the predictable side effects of cabazitaxel, and practical guidance on how these can be prevented, minimised and treated.
I hope you will agree that these articles provide a welcome and informative resource at an exciting time in uro-oncology--possibly the dawn of an era in which mCRPC may change from being a 'terminal' illness, to one manageable by ongoing, 'chronic' therapy.
